Medtronic (MDT)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$104.96+6.15%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · MDT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 7.3% |
| Our one-year growth estimate | diamond | 4.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 2.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
MDT — CEO transition
Dated 2026-10-19
President — Michael Marinaro: The filing discloses the internal promotion of Michael Marinaro to President with expanded responsibilities, which is a standard succession or role expansion event rather than a departure.
Why it matters: Cardiac Ablation Solutions grew 88% in Q1 FY27. Continued growth would support a key new growth platform.
Supportive ifThe next report shows Cardiac Ablation Solutions revenue growth at or above 50% year over year.
Worry ifThe next report shows Cardiac Ablation Solutions growth below 20% year over year, or a decline.
Why it matters: FY26 non-GAAP EPS grew only 0.7%, while Medtronic now guides to $5.94 to $6.00 for FY27. A stronger quarter would support that target.
Supportive ifQ2 FY27 non-GAAP diluted EPS is above the year-ago quarter and FY27 guidance stays at $5.94 or higher.
Worry ifQ2 FY27 non-GAAP diluted EPS is below the year-ago quarter, or FY27 guidance falls below $5.94.
Why it matters: FY26 non-GAAP operating margin fell 130 basis points. Q1 FY27 margin rose only 10 basis points, leaving room to test cost control.
Supportive ifQ2 FY27 non-GAAP operating margin rises at least 50 basis points from the same quarter a year ago.
Worry ifQ2 FY27 non-GAAP operating margin is flat or lower year over year.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$113 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $227 loss on $10,000 · 2.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,891 loss on $10,000 · 28.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.